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Background: The Japan EPA Lipid Intervention Study (JELIS) demonstrated the efficacy of eicosapentaenoic acid (EPA) in preventing coronary 
artery disease (CAD) in hypercholesterolemic patients by mechanisms other than LDL-cholesterol (C) lowering. The aim of this study was to examine 
the effects of EPA on coronary plaque stabilization by multi-detector row computed tomography (MDCT). 
Methods: A total of 51 lesions in 43 patients with suspected CAD (<75% stenosed vessels) and a LDL-C level of <160mg/dL were enrolled. The 
patients were randomly assigned to receive EPA or ezetimibe. Blood samples were collected to measure serum lipids and changes in coronary 
plaques were evaluated by MDCT at baseline and at a 1-year follow-up. 
Results: Compared with the baseline, the EPA/ arachidonic acid ratio was significantly increased in the EPA group, whereas the LDL-C levels were 
reduced in the ezetimibe group but not in the EPA group. Cross-sectional multiplanar reconstruction of MDCT images showed a significant reduction 
of the soft plaque volume in the EPA group but not in the ezetimibe group at follow-up. There were significant improvements in the plaque area, 
lumen area and soft plaque volume in the EPA group compared with the ezetimibe group. The incidence of major cardiovascular events were lower in 
the EPA group than in the ezetimibe group (9.5% vs. 36.4%, p=0.03 by log-rank test). 
Conclusions: The current data suggest that EPA has beneficial effects on coronary plaque stabilization, independent of the LDL-C level. 
Table. Cross-sectional vessel and plaque measured by MDCT and lipid profiles at baseline and follow-up.
EPA Ezetimibe p-valuea)
baseline follow-up %change baseline follow-up %change
LDL-C: mg/dL 112.3±24.4 106.9±26.5 -4.4±15.9 116.6±28.9 94.4±21.8** -16.5±20.1 0.034
EPA/AA ratio 0.40±0.20 1.34±0.34*** 308.4±197.0 0.41±0.24 0.39±0.18 8.5±52.5 <0.001
Vessel area: mm2 20.4±7.3 19.9±7.4 -0.7±18.4 16.1±4.3 16.3±5.8 1.0±16.9 0.735
Lumen area: mm2 7.7±4.8 8.2±5.0 8.0±22.8 6.8±3.5 5.7±3.7** -16.8±32.8 0.004
Plaque area: mm2 12.7±5.0 11.7±5.0 -3.5±28.7 9.3±3.3 10.7±4.0 19.5±36.3 0.017
Plaque component 
(volume:%)
50-120 HU 56.5±8.0 56.9±9.1 1.2±13.2 60.3±10.6 56.8±12.1* -5.5±14.9 0.101
0-50 HU 19.2±3.6 17.6±3.8 -6.1±23.4 18.2±6.1 18.7±5.8 7.4±30.5 0.090
-50-0 HU 10.0±4.6 7.5±3.6** -16.3±37.6 7.6±4.6 8.2±6.3 15.1±60.7 0.036
Data are mean±SD. *p<0.05, **p<0.01, ***p<0.001 vs. baseline, respectively (paired t-test). a) Differences in %change between the two groups 
(unpaied t-test). EPA: eicosapentaenoic acid, AA: arachidonic acid. HU: hounsfield unit.
